Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-26T04:29:17.563Z Has data issue: false hasContentIssue false
  • English
  • Français

Outcome of Stereotactic Radiotherapy for Patients with Uncontrolled Acromegaly

Published online by Cambridge University Press:  02 December 2014

Syed Ali Imran ,
Ian G. Fleetwood ,
Colleen M. O'Connell ,
Thomas P. Ransom ,
Liam A. Mulroy ,
Ehud Ur  and
David B. Clarke
Syed Ali Imran
Affiliation:
Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
Ian G. Fleetwood
Affiliation:
Halifax Neuropituitary Program and Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada
Colleen M. O'Connell
Affiliation:
Perinatal Epidemiology Research Unit, Dalhousie University, Halifax, Nova Scotia, Canada
Thomas P. Ransom
Affiliation:
Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
Liam A. Mulroy
Affiliation:
Radiation Oncology, Dalhousie University, Halifax, Nova Scotia, Canada
Ehud Ur
Affiliation:
Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
David B. Clarke*
Affiliation:
Halifax Neuropituitary Program and Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada
*
Halifax Neuropituitary Program, Division of Neurosurgery, 1796 Summer Street, Room 3807, Halifax, Nova Scotia, B3A 3A7, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

Linear accelerator based stereotactic radiation therapy (SRT) has been used for the treatment of pituitary tumours; however, little is known concerning the use of this modality for the treatment of patients with acromegaly. We have prospectively studied the short-term outcome of SRT in 12 acromegaly patients who failed to achieve biochemical remission despite surgery and/or pharmacologic therapy.

Methods:

We identified all patients who had biochemically uncontrolled acromegaly and were treated with SRT between April 2003 and December 2006. All patients were followed prospectively based on a pre-defined protocol that included Goldman visual field examination, MRI of the sella, and pituitary hormone testing at 3, 6, 12 months, and then yearly.

Results:

A total of 12 patients with acromegaly were treated with SRT. There were 9 females and the median age of the group was 50 years. The median follow-up was 28.5 months during which time the mean tumor volume decreased by 40%, the median GH fell from 4.1 μg/L to 1.3 μg/L (p=0.003) and the median IGF-1 dropped more than half from 545.5 μg/L to 260.5 μg/L (p=0.002). Four patients achieved normal, while an additional 2 achieved near-normal, IGF-1 levels. One patient was able to discontinue and two were able to reduce their acromegaly medications while maintaining a normal IGF-1. A new pituitary hormonal deficit was found at 24 months in one patient who developed hypoadrenalism requiring corticosteroid replacement.

Conclusion:

Based on our early experience, we believe that SRT should be considered in treating patients with uncontrolled acromegaly.

Résumé:

RÉSUMÉ:Objectif :

La radiothérapie stéréotaxique (RTS) par accélérateur linéaire est utilisée pour le traitement des tumeurs hypophysaires. Cependant, on connaît peu de choses sur l’utilisation de ce mode de traitement chez les patients atteints d’acromégalie. Nous avons étudié de façon prospective le résultat thérapeutique à court terme de la RTS chez 12 patients atteints d’acromégalie, chez qui la chirurgie et/ou la pharmacothérapie n’a pas provoqué de rémission biochimique.

Méthodes :

Nous avons identifié tous les patients dont l’acromégalie n’était pas maîtrisée au point de vue biochimique, qui ont été traités par RTS entre avril 2003 et décembre 2006. Tous les patients ont été suivis de façon prospective selon un protocole prédéterminé comportant un examen des champs visuels (Goldman), une IRM de la selle turcique et un bilan hormonal hypophysaire après 3, 6, et 12 mois, puis annuellement.

Résultats :

Douze patients atteints d’acromégalie, dont 9 femmes, ont été traités par RTS. L’âge médian des patients était de 50 ans et le suivi médian était de 28,5 mois. Le volume moyen de la tumeur a diminué de 40%, le taux médian de somatotrophine est passé de 4,1 μg/L à 1,3 μg/L (p = 0,003) et le taux médian d’IGF-1 a chute de plus de la moitié, passant de 545,5 μg/L à 260,5 μg/L (p = 0,002). Le taux d’IGF-1 est redevenu normal chez quatre patients et quasi normal chez deux autres. Un patient a pu cesser de prendre ses médicaments pour traiter l’acromégalie et deux autres ont pu en réduire la posologie tout en maintenant un IGF-1 normal. Un nouveau déficit hormonal hypophysaire a été constaté chez un patient après 24 mois de suivi, soit un hypoadrénalisme nécessitant un remplacement par des corticostéroïdes.

Conclusion :

Suite à ces premières observations, nous croyons que la RTS devrait être envisage chez les patients qui présentent une acromégalie rebelle.

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 36 , Issue 4 , July 2009 , pp. 468 - 474
Copyright
Copyright © The Canadian Journal of Neurological 2009

References

1. Gramegna, A. Revue neurologique. 1909; (17):15–7.Google Scholar
2. Landolt, AM, Haller, D, Lomax, N, Scheib, S, Schubiger, O, Siegfried, J, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg. 1998 Jun; 88(6): 1002–8.Google Scholar
3. Losa, M, Gioia, L, Picozzi, P, Franzin, A, Valle, M, Giovanelli, M, et al. The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab. 2008 Jul; 93(7): 2546–52.Google Scholar
4. Vik-Mo, EO, Oksnes, M, Pedersen, PH, Wentzel-Larsen, T, Rodahl, E, Thorsen, F, et al. Gamma knife stereotactic radiosurgery for acromegaly. Eur J Endocrinol. 2007 Sep; 157(3): 255–63.Google Scholar
5. Robar, JL, Clark, BG, Schella, JW, Kim, CS. Analysis of patient repositioning accuracy in precision radiation therapy using automated image fusion. J Appl Clin Med Phys. 2005; 6(1): 71–83.Google Scholar
6. Giustina, A, Barkan, A, Casanueva, FF, Cavagnini, F, Frohman, L, Ho, K, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000 Feb; 85(2): 526–9.Google ScholarPubMed
7. Gittoes, NJ, Sheppard, MC, Johnson, AP, Stewart, PM. Outcome of surgery for acromegaly-the experience of a dedicated pituitary surgeon. Q J Med. 1999 Feb; 92(12): 741–5.Google Scholar
8. Shimon, I, Cohen, ZR, Ram, Z, Hadani, M. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery. 2001 Jun; 48(6): 1239–43.Google ScholarPubMed
9. Melmed, S. Medical progress: acromegaly. N Engl J Med. 2006 Dec 14; 355(24): 2558–73.Google Scholar
10. Jaffe, CA, Barkan, AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am. 1992 Sep; 21(3): 713–35.CrossRefGoogle ScholarPubMed
11. Jackson, SN, Fowler, J, Howlett, TA. Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol (Oxf). 1997 Jun; 46(6): 745–9.Google Scholar
12. Freda, PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2002 Jul; 87(7): 3013–8.Google Scholar
13. Trainer, PJ, Drake, WM, Katznelson, L, Freda, PU, Herman-Bonert, V, van der Lely, AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000 Apr 20; 342(16): 1171–7.CrossRefGoogle ScholarPubMed
14. van der Lely, AJ, Hutson, RK, Trainer, PJ, Besser, GM, Barkan, AL, Katznelson, L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001 Nov 24; 358(9295): 1754–9.Google Scholar
15. Castinetti, F, Taieb, D, Kuhn, JM, Chanson, P, Tamura, M, Jaquet, P, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab. 2005 Aug; 90(8): 4483–8.Google Scholar
16. Jenkins, PJ, Bates, P, Carson, MN, Stewart, PM, Wass, JA. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab. 2006 Apr; 91(4): 1239–45.Google Scholar
17. Barkan, AL, Halasz, I, Dornfeld, KJ, Jaffe, CA, Friberg, RD, Chandler, WF, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab. 1997 Oct; 82(10): 3187–91.Google Scholar
18. Cozzi, R, Barausse, M, Asnaghi, D, Dallabonzana, D, Lodrini, S, Attanasio, R. Failure of radiotherapy in acromegaly. Eur J Endocrinol. 2001 Dec; 145(6): 717–26.Google Scholar
19. Brada, M, Ford, D, Ashley, S, Bliss, JM, Crowley, S, Mason, M, et al. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. Br Med J. 1992 May 23; 304 (6838): 1343–6.CrossRefGoogle ScholarPubMed
20. Simmons, NE, Laws, ER Jr. Glioma occurrence after sellar irradiation: case report and review. Neurosurgery. 1998 Jan; 42 (1): 172–8.Google Scholar
21. Wass, JA. Evidence for the effectiveness of radiotherapy in the treatment of acromegaly. J Endocrinol. 1997 Oct; 155 Suppl 1: S57–8.Google Scholar
22. Plowman, PN. Pituitary adenoma radiotherapy-when, who and how? Clin Endocrinol (Oxf). 1999 Sep; 51(3): 265–71.CrossRefGoogle Scholar
23. Pollock, BE, Kondziolka, D, Lunsford, LD, Flickinger, JC. Stereotactic radiosurgery for pituitary adenomas: imaging, visual and endocrine results. Acta Neurochir Suppl. 1994; 62: 33–8.Google Scholar
24. Hayashi, M, Izawa, M, Hiyama, H, Nakamura, S, Atsuchi, S, Sato, H, et al. Gamma Knife radiosurgery for pituitary adenomas. Stereotact Funct Neurosurg. 1999; 72 Suppl 1: 111–8.Google Scholar
25. Zhang, N, Pan, L, Wang, EM, Dai, JZ, Wang, BJ, Cai, PW. Radiosurgery for growth hormone-producing pituitary adenomas. J Neurosurg. 2000 Dec; 93 Suppl 3: 6–9.Google Scholar
26. Jezkova, J, Marek, J, Hana, V, Krsek, M, Weiss, V, Vladyka, V, et al. Gamma knife radiosurgery for acromegaly-long-term experience. Clin Endocrinol (Oxf). 2006 May; 64(5): 588–95.Google Scholar
27. Powell, JS, Wardlaw, SL, Post, KD, Freda, PU. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab. 2000 May; 85(5): 2068–71.Google Scholar
28. Jackson, IM, Noren, G. Role of gamma knife therapy in the management of pituitary tumors. Endocrinol Metab Clin North Am. 1999 Mar; 28(1): 133–42.Google Scholar
29. Ikeda, H, Jokura, H, Yoshimoto, T. Transsphenoidal surgery and adjuvant gamma knife treatment for growth hormone-secreting pituitary adenoma. J Neurosurg. 2001 Aug; 95 (2): 285–91.Google Scholar
30. Attanasio, R, Baldelli, R, Pivonello, R, Grottoli, S, Bocca, L, Gasco, V, et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab. 2003 Nov; 88(11): 5258–65.Google Scholar
31. McClelland, S III, Higgins, PD, Gerbi, BJ, Orner, JB, Hall, WA. Fractionated stereotactic radiotherapy for pituitary adenomas following microsurgical resection: safety and efficacy. Technol Cancer Res Treat. 2007 Jun; 6(3): 177–80.Google Scholar
32. Landolt, AM, Lomax, N, Scheib, SG, Wellis, G. Endocrine results of gamma knife radiosurgery in acromegaly and prolactinomas. In: Kondziolka, D, editor. Radiosurgery. Basel: 2002. p. 87–92.CrossRefGoogle Scholar
33. Pollock, BE, Jacob, JT, Brown, PD, Nippoldt, TB. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg. 2007 May; 106(5): 833–8.Google Scholar
34. Attanasio, R, Epaminonda, P, Motti, E, Giugni, E, Ventrella, L, Cozzi, R, et al. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab. 2003 Jul; 88(7): 3105–12.Google Scholar